PATENT CLAIM ANALYSIS

Application Number: 16001697
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-10
Patent Classification: ["514", "226500"]

Abstract:
Disclosed herein are compositions comprising a drug such as a triptan (e.g. rizatriptan) and/or an NSAID (e.g. meloxicam) in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability, solubility, or pharmacokinetics of the drug for the treatment of conditions such as pain.

Claim (Index 14):
The method of  claim 1 , wherein 15 minutes after the dosage form is orally administered, the amount of the meloxicam dissolved in the stomach fluid of the human being is greater than the amount of the meloxicam that would be dissolved in the stomach fluid of the human being as a result of orally administering a reference dosage form containing: 1) the same amount of meloxicam, and 2) no bicarbonate.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 94.0
- Lexical Diversity: 1.52273
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15976800', '15936176', '15986215', '16000701', '15984055']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8247749642947053
- 35 USC 102 Novelty (BERT): 0.5807307480049821
- Combined Prediction Score: 0.8003705426657329
- Mean Citation Score: 422.436214
- Max Citation Score: 479.27145
- Similarity Product: 351.2197202972174

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test